# Innovative Technologies for the Treatment of Pulmonary and Heart Failure

Study · id `cardio:ct-nct05090930` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05090930](<https://clinicaltrials.gov/study/NCT05090930>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05090930

Browse, organ or system: Heart  
Browse, condition area: Acute care and long-term living  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT05090930. Non-randomized; no masking; primary purpose treatment. Start 2021-01-01 (actual); primary completion 2023-07-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT05090930, source copy `cardio:ctgov-nct05090930-2021-10-25`, retrieved 2026-10-31)
- Started: 2021-01-01 (actual) (ClinicalTrials.gov record NCT05090930, source copy `cardio:ctgov-nct05090930-2021-10-25`, retrieved 2026-10-31)
- Primary completion: 2023-07-01 (anticipated) (ClinicalTrials.gov record NCT05090930, source copy `cardio:ctgov-nct05090930-2021-10-25`, retrieved 2026-10-31)
- Completion: 2023-12-01 (anticipated) (ClinicalTrials.gov record NCT05090930, source copy `cardio:ctgov-nct05090930-2021-10-25`, retrieved 2026-10-31)
- Countries: Kazakhstan (ClinicalTrials.gov record NCT05090930, source copy `cardio:ctgov-nct05090930-2021-10-25`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05090930-2021-10-25`, retrieved 2026-10-31)

## The registry's words

- Brief title: Innovative Technologies for the Treatment of Pulmonary and Heart Failure
- Condition: Cardiogenic Shock
- Condition: Ventricular Arrythmia
- Condition: Cardiac Arrest With Successful Resuscitation
- Condition: Sepsis
- Condition: Multiple Organ Failure
- Condition: Pulmonary Failure
- Condition: Decompensated Heart Failure
- Condition: Acute Heart Failure
- Intervention (Device): HA330 - Jafron Biomedical Co., Ltd., China - extracorporeal hemocorrection
- Intervention (Device): CytoSorb (CytoSorbents Corp., USA) - an extracorporeal cytokine adsorber
- Lead sponsor: National Research Center for Cardiac Surgery, Kazakhstan
- Lead sponsor class: OTHER
- Collaborator: Ministry of Education and Science, Republic of Kazakhstan
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Cardiogenic shock (`cardio:cardiogenic-shock`)

## Provenance

Content hash: 22e7dffcdb3be5c7827f9129c6c87fc7e554d17efd9b9b65aa58e56c88f6d8e3
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
